header7;header;
 
 
 
 
 
 
 
 
 
  Quarterly Shareholder Update: 02/24/2011
   
 
   
 
   
Provides the earliest detection of glaucoma through its objective 90 second long PERG test. It analyzes the functionality of ganglion cells and identifies glaucoma suspects well before perimetry can detect visual field loss. Unlike imaging techniques of the optic disk and retinal nerve fiber layer, which only provide a measure of missing ganglion cells and their axons,
PARAMAX provides a measure of both missing and dysfunctional ganglion cells. 		 
   
   
DEFINE THE PROGRESSION OF GLAUCOMA WITH PARAMAX
   
   
   
PARAMAX and its upgrade PARAMAX OMNI are essential for multiple types of specialists.  
 
   
 
TEST Examples of Early Discovery and Diagnosis Possible
 • Pattern Electroretinogram    (PERG)*  • Glaucoma
 • Electroretinogram (ERG)*  • Rod, cone, and retinal vascular    diseases
 • Pigmented retinopathy
 • Age related maculopathy
 • Visual Evoked Potential    (VEP)*  • Amblyopia
 • Optic neuritis
 • Multiple sclerosis suspects
 • Electrooculogram (EOG)*  • Vitelliform macular dystrophy
 • Electronystagmogram (ENG)*  • Nystagmus
 • Multifocal ERG (mfERG)†  • Optic nerve or retinal disease
 • The various dot syndromes
 • Multifocal PERG (mfPERG)†  • Chloroquine retinopathy
 • Multifocal VEP (mfVEP)†  • Visual field abnormalities
* Available in PARAMAX and PARAMAX OMNI
† Available exclusively in PARAMAX OMNI
   
   
Currently Under FDA Review  
   
 
   
Brochure PDF  
   
BETTER PROCEDURE  
   
PARAMAX identifies dysfunctional ganglion cells
to allow for early treatment before permanent loss
of ganglion cells and vision can develop.		  
   
   
   
   
   
   
   
   
GOOD PROCEDURES  
   
With current imaging technologies and
field perimetry, ganglion cell loss is
defined, but damage has already occured.		  
 
 
 
Copyright (c) 2010 - Paradigm Medical Industries, Inc. - All Rights Reserved